Breadcrumb other pages


  • Overview

With the support of previous H2020-funded projects, the ERINHA Research Infrastructure was successfully set up and has now entered into its operational phase. ERINHA-Advance is a H2020-funded project which aims to continue supporting the successful operation of the ERINHA Research Infrastructure to ensure its long-term sustainability. To this end, the project focuses on a number of priorities:


  • increase the number of members’ of ERINHA and thus the research capacities offered to potential users;
  • reinforce ERINHA’s European and International cooperation with relevant countries, initiatives and networks;
  • improve users’ services by testing the operability of the infrastructure through pilot activities;
  • stimulate the innovation potential of ERINHA through collaboration endeavours with industry;
  • strengthen the service provision framework with data management and data-sharing rules, clarification of IPR regimes and a solid quality assurance system for the RI and its national nodes;
  • reinforce ERINHA’s capacities through training activities;
  • communicate broadly on ERINHA’s services;
  • ensure compliance with the ethics requirements.


The project started on the 1st of January 2019 and will run until the 31st of December 2021.

Coordinated by ERINHA AISBL (Belgium) with the support of Inserm Transfert (France), the consortium brings together 11 partners from 8 European countries (Belgium, France, Portugal, Sweden, Hungary, Italy, Austria and Germany). 5 of these 8 European countries possess national BSL4 facilities (Inserm France, FoHM Sweden, NPHC Hungary, INMI Italy, BNI Germany), 4 of them (KUL Belgium, INSA Portugal, KI Sweden, MUG Austria) have complementary facilities essential for a research infrastructure dedicated to the study of high-consequence pathogens of Risk Group 4 (RG4). 4 of the 5 ERINHA AISBL members belong to the ERINHA-Advance consortium (Inserm, INSA, FoHM and NPHC).


The project is coordinated by Hervé Raoul, Director General of the ERINHA RI with the support of the infrastructure’s Central Coordinating Unit (CCU) and Inserm Transfert which forms the Project Management Team.

Hervé Raoul, Director General of ERINHA & coordinator of ERINHA-Advance.

The Executive Committee, composed of the WorkPackage leaders, ensures that the project runs smoothly from a technical point of view and submits any important decisions to the Governing Board for approval when necessary. The Governing Board is made up of one representative from each consortium member.

ERINHA-Advance advisory boards

The boards set up by the ERINHA Research Infrastructure will also advise ERINHA-Advance on the project progress: an Independent Advisory Board and a Board of Industrial Representatives.

The ERINHA-Advance project is organized into 7 Workpackages – working groups dedicated to a specific set of activities.  

WP1 (ERINHA/IT) aims to manage the project, including communication with the European Commission, financial management, preparation of periodic progress and financial reports.

WP2 (ERINHA/NKK) aims to increase the membership of the Research Infrastructure within the EU and to further develop international links outside Europe in order to reinforce the sustainability of ERINHA and increase Europe’s preparedness level if faced with an epidemic involving RG4 or unknown pathogens.

WP3 (INSERM/FoHM) aims to improve ERINHA AISBL users’ services through the implementation of excellence-driven pilot calls for access to ERINHA facilities. Two programmes will be developed: one on the development of innovative animal models for highly infectious agents and another on an innovative therapeutic approach for RG4 pathogens. The success of this WP will feed into WP2 and WP4.

WP4 (FoHM/ERINHA) aims to stimulate and promote the use of ERINHA services by industrial partners and SMEs in order to facilitate the interaction with European industrial and commercial partners and to identify the opportunities of co-innovation for developing equipment/technologies for ERINHA member facilities.

WP5 (ERINHA/INSA) aims to ensure the sustainability and effectiveness of high quality ERINHA services provided to private and public entities by implementing a quality management system, an effective IPR and ethical framework and a comprehensive data management and policy plan. The success of this WP will contribute to WP2, WP3 and WP4.

WP6 (ERINHA/NKK) aims to reinforce the capacity building of the Human Resources of ERINHA, and to communicate and disseminate the progress and results of all WPs.

WP7 aims to ensure compliance with the ethics requirements set out for this WP.

ERINHA-Advance first TransNational Access Call : Deadline Expired

Through the EU funded H2020 project ERINHA-Advance, we are now opening our first call for proposals to offer scientists free of charge* transnational access (TNA) to ERINHA’s full catalog of services, including access to cutting edge high containment facilities.
* Free of charge transnational access includes administrative & logistical support, free use of the installations, in accordance with all applicable national laws, local safety and health regulations, and technical and scientific support. It does not include any other costs (travel and/or subsistence costs; consumables; animals; etc…).

ERINHA AISBL has aligned its scientific strategy with the WHO Blueprint list of priority diseases and will therefore prioritize applications related to the following pathogens:

  • Ebola virus
  • Marburg virus
  • Lassa virus
  • Crimean-Congo Hemorrhagic Fever virus
  • Nipah virus

In addition, applications must fall into one of the following scientific topics:

SECTION 1: Innovative therapeutics, vaccines or diagnosis approaches for RG4 pathogens

  • Development of RG4 pathogens’ standards for diagnosis
  • Development of innovative technologies for diagnosis
  • Development of innovative alternatives for antibodies production for diagnosis and therapeutics purpose
  • Development of innovative therapeutics tools/ immunotherapy
  • Development of new synthetic methods to improve immunogenicity of vaccines
  • Development of new approach for the design of antiviral drugs
  • Development of vaccines against RG4 pathogens

SECTION 2: Innovative approaches to study highly infectious viruses in animal experimentation

  • Optimization/ adaptation of rodent models
  • Development of telemetry technics/ biochemistry technics for animal experimentation
  • Development and optimization of alternative technologies to animal models
  • Development of innovative real-time imaging capacity in BSL-4 conditions

If you are currently working on a project that meets the above requirements, this is a unique opportunity to avail of ERINHA services and expertise, and:

  • Perform a final step of validation
  • Perform a preliminary study
  • Adapt methods & approaches to highly pathogenic viruses

For more information about our TNA Programme, including the conditions for access & eligibility, and the selection process, please see our TNA Guidelines, or contact our staff at the Central Coordinating Unit

To participate in the call, please download the following documents:


Opening of the call: 15 October 2019
Submission deadline: 15 December 2019
Evaluation and Selection deadline: February 2020
Feedback to applicants: March 2020

ERINHA Advance has partnered with TRANSVAC2, a collaborative infrastructure project funded by the European Commission and coordinated by the European Vaccine Initiative (EVI). TRANSVAC2 is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of vaccine projects by implementing a permanent research infrastructure. ERINHA Advance’s 1st TNA call and TRANSVAC’s 7th call for proposals have been launched simultaneously. Applicants with interest in highly pathogenic agents and vaccine development are encouraged to apply to both calls. For more information on TRANSVAC’s current call for TNA services, please go to

Sign up to receive the ERINHA newsletter:

ERINHA-Advance annual meeting 26-27 February 2020

The 1st annual meeting will take place in Lisbon, Portugal on the 4-5 February 2020. Hosted by consortium partner INSA.

ERINHA-Advance 3rd ExCom 10-11 October 2019

The 3rd ERINHA-Advance Executive Committee meeting was held in Paris at ERINHA and Inserm’s headquarters on the 10-11 October 2019. The meeting was an opportunity to review the progress of the project since its beginning and receive comments from the Independent Advisory Board.

ERINHA-Advance Kick-off meeting

The kick-off meeting of the ERINHA-Advance project was held in Paris on the 12-13 February 2019. All members of the consortium were present. The project Executive Committee also convened for its first meeting at the same time.

Below you’ll find a list of ERINHA’s main publications, communication tools and all public deliverables produced in the framework of the project:


ERINHA has developed its scientific strategy – a Research Portfolio, which is an evolving strategy with systematic updates to match with European and Global Research and Innovation and Public Health needs. It presents ERINHA’s prioritized pathogens, built on the WHO R&D Blueprint.


The ERINHA Research Infrastructure at a glance

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824061.